test

A Multi-center pilot study of the effect of Sorafenib on Portal Pressure in Patients with Cirrhosis, Significant Portal Hypertension and Hepatocellular Carcinoma

Conditions

Hepatocellular Carcinoma | Liver

Trial Phase

Phase Pilot

Trial Purpose and Description

Trial Purpose

You are free to choose not to participate and if you do become a subject you are free to withdraw from this study at any time during its course. If you choose not to participate or if you withdraw it will not harm your relationship with your own doctors or with Yale-New Haven hospital. If you do become a subject, you are free to stop and withdraw from this study at any time during its course. If you sign this authorization, you may change your mind at any time, but the researchers may continue to use information collected before you changed your mind to complete the research. To withdraw, you can call a member of the research team at any time and tell them that you no longer want to take part. This will cancel any appointments in the future. You must also follow up your phone call by sending a written notice to revoke this authorization to the principal investigator, Dr. Strazzabosco, Internal Medicine - Digestive Diseases, PO BOX 208019, New Haven, CT 06520-8019. Before you make your decision, a member of the research team will be available so that you can ask any questions you have about the research project. You can ask for any information you want. Sign the consent form only after you have had a chance to ask your questions and have received satisfactory answers If you decide to withdraw from this project, please notify a member of the research team before you withdraw. This notice will allow that person or the research supervisor to inform you if there are any health risks or special requirements linked to withdrawing.


Participation Guidelines

Age:
20 Years - 75 Years
Gender:
Both

Eligibility Criteria

Inclusion Criteria

  • Age 20-75 years
  • Cirrhosis diagnosed by liver biopsy or by imaging studies showing a nodular liver, splenomegaly and/or collaterals
  • HCC proven histologically or diagnosed following the AASLD criteria if biopsy not feasible or refused by the patient
  • HCC must be unresectable and within UCSF criteria (single tumor &le 6.5 cm diameter, or, if multiple lesions, maximum diameter of the largest lesion &le 4.5 and total tumor diameter &le 8 cm (23))
  • CPT score <9 (that is all Child A and Child B with a score of 7 or 8)
  • Complete response ttreatment with RFA (including that performed laparoscopically) or TACE or a combination of the above as defined by radiologic criteria (hepatoma protocol MRI or CT scan performed 4-6 weeks after the procedure).
  • Nmore than twablative procedures prior tenrollment
  • Clinically significant portal hypertension , as defined by HVPG ³10mmHg
  • EGD for variceal screening performed within 6 months of entry intthe study unless the patient is already on a stable dose of a non selective beta-blocker (adjusted tobtain a heart rate of 55-60 bpm) or treated with variceal band ligation.
  • Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior tthe start of treatment
  • Women of childbearing potential and men must agree tuse adequate contraception (barrier method of birth control) prior tstudy entry and for the duration of study participation. Men should use adequate birth control for at least three months after the last administration of sorafenib.
  • Signed informed consent
Sponsor:
Bayer
Onyx Pharmaceuticals
Yale Cancer Center
Dates:
02/17/2011
Last Updated:
Study HIC#:
1002006266